The MIF Invests in Luminary Therapeutics, KAHR, and Telo Therapeutics to Accelerate Novel Therapies for the
Telo Therapeutics is developing orally bioavailable next generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. Our Development candidate, TSM74, is a novel targeted protein degrader of XPO1, a clinically validated oncology target relevant to a wide-range of solid and hematological cancers.
TSM74’s unique chemistry and distinct mechanism of action result in a dramatically improved safety profile compared to existing toxic covalent inhibitors, leading to rapid tumor regressions and complete tumor removal across multiple preclinical cancer models.